Sex: U
Vaccine: COVID19
Symptoms: Ophthalmic herpes simplex, Ophthalmic herpes zoster
Clinical narrative: Herpes zoster ophthalmic; Herpes Simplex Ophthalmicus; This solicited report received from a physician by COV19VAC-NONCOMP: Jansen COVID 19 Non Company Solicited Study. This report was referenced in literature:  and concerned a patient of unspecified age and sex (subject number and site number were not reported). The patient's height and weight were not reported. Age at time of vaccination was unknown. Aim- The aim of this study was to evaluate the cases of herpes simplex and zoster ophthalmicus after SARS-CoV-2 vaccination and assess the clinical presentations in patients. The aim of this study was to evaluate the cases osimplex and zoster   No past medical history, concurrent conditions or pre-existing medical conditions were reported.  The patient received janssen covd-19 vaccine (suspension for injection, intramuscular, batch number not reported) dose, frequency and therapy dates not reported, for covid-19 prophylaxis. Additional dosage information included: dose series 1. The batch number was not reported. The company is unable to perform follow up. Method- A retrospective analysis of cases reported to the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS) between December 11, 2020, and July1, 2022. Patients diagnosed with herpes simplex ophthalmicus (HSO) and herpes zoster ophthalmicus (HZO) after vaccination withBNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and Ad26.-COV2.S (Janssen) were included in the study. We performed adescriptive analysis of patient demographics, history, and ophthalmic and systemic clinical presentations. The correlations between vaccine type and continuous variables were assessed by the one-way analysis of variance test. In addition, we used the Pearsonx2test to assess the association between 3 vaccines and categorical variables. A post hoc analysis was performed between HSO and HZO onset intervals after vaccination, dose, and vaccine type. The 30-day risk analysis was also performed for HSO and HZO onset postvaccination using the reverse Kaplan-Meier analysis. Result- A total of 1180 cases of HZO (983, 83.30%) and HSO (180,15.25%) were reported. The mean age of patients with HZO and HSO was 59.02619.05 and 52.68617.83 years, respectively. Most of the cases of HZO (795, 80.87%) and HSO (131, 72.78%) were reported inpatients who received BNT162b2. In the cohort, 63.28% and 65.56%diagnosed with HZO and HSO were women. About one third of HZO(36.52%) and HSO (35.56%) cases were reported after the first dose. More than half of the cases of HZO (61.34%) and HSO (64.45%) were reported within the first 2 weeks after vaccination. The estimated crude reporting rate (per million doses) in the United States was 0.25, 0.22,and 0.47 for BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively. The onset interval for HZO was significantly shorter in patients who received BNT162b2 (20.51656.20 days, P= 0.030) compared with patients who received mRNA-1273 (36.566108.67 days) andAd26.COV2.S (39.66660.15 days) vaccines. The 30-day risk analysis showed a significantly higher risk of HZO after BNT162b2than the other 2 vaccines (P= 0.011).  No concomitant medications were reported.  On an unspecified date, the patient experienced herpes zoster ophthalmic (dose series 1) and herpes simplex ophthalmicus  (dose series 1).  The action taken with covid-19 vaccine ad26.cov2.s was not applicable.  The outcome of herpes zoster ophthalmic and herpes simplex ophthalmicus was not reported.  The reporter considered the causality between covid-19 vaccine ad26.cov2.s and herpes zoster ophthalmic and herpes simplex ophthalmicus as related. Company causality between covid-19 vaccine ad26.cov2.s and herpes zoster ophthalmic and herpes simplex ophthalmicus was not related. Conclusion- The low crude reporting rate suggests that HZO and HSO after SARS-CoV-2 vaccination occur rarely. This study provides insights into the possible temporal association between reported HSO and HZO after SARS-CoV-2 vaccines; however, further investigations are required to delineate the possible underlying immunological mechanisms.   This report was serious (other medically important condition).; Sender's Comments: V0-Ophthalmic herpes zoster, Ophthalmic herpes simplex. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event. Specifically: MEDICAL HISTORY (Diabetes). Therefore, this event is considered inconsistent with vaccine administration.